Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.
Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaudé S, Enzmann V, Sarra GM.
Retina · research support, non-u.s. gov't; journal article · DOI 10.1097/iae.0b013e31821e2070 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rasagiline. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
15 hitsType A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M.
J Neural Transm (Vienna) · research support, non-u.s. gov't; journal article · DOI 10.1007/s00702-011-0730-6Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM, LEGATO Investigators.
Neurologist · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1097/nrl.0b013e31822f6872Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
Chitnis S, Jaffery M, Dewey RB.
Int J Neurosci · comparative study; clinical trial; journal article; research support, n.i.h., extramural · DOI 10.3109/00207454.2011.617016Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
Jenner P, Langston JW.
Mov Disord · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1002/mds.23926Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.
Gardoni F, Zianni E, Eramo A, Canonico PL, Di Luca M.
Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2011.09.028Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F, Rabey JM.
Eur J Neurol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1468-1331.2011.03512.xEfficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E, Stern MB.
Eur J Neurol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1468-1331.2011.03484.xDetermining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Silver DE, Buck PO.
Int J Neurosci · review; journal article · DOI 10.3109/00207454.2011.582240Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.
Levkovitch-Verbin H, Vander S, Melamed S.
J Glaucoma · journal article · DOI 10.1097/ijg.0b013e3181e3d101The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ, Wilkinson JR.
J Clin Pharmacol · review; journal article · DOI 10.1177/0091270011406279The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahin HA, Emre M.
Mov Disord · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/mds.23738A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
Lancet Neurol · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(11)70073-4Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA.
Int Rev Neurobiol · review; journal article · DOI 10.1016/b978-0-12-386467-3.00007-8Rasagiline in Parkinson's disease.
Chahine LM, Stern MB.
Int Rev Neurobiol · review; journal article · DOI 10.1016/b978-0-12-386467-3.00008-x